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Lupusnephritis,whichhasvarioushistologicalpatternsandvariableclinicaloutcomes,isoneofthemostimportantcomplications
of systemic lupus nephritis (SLE). This pathogenetic mechanism in each histologically diﬀerent type of lupus nephritis (LN)
remains unclear. Although SLE is suggested to be a Th2-driven disease, elevation of both Th1 and Th2 cytokines occurs in both
humans and mice, suggesting that SLE is a complex disease driven by diﬀerent lymphocyte subsets with high heterogeneity of
clinical manifestations and organ involvement. Recent ﬁndings in LN elucidate an essential role for the Th1, IL-17 producing T
cells and Th17 cells in the development of diﬀuse proliferative lupus nephritis (DPLN), and Th2 cytokine in that of membranous
lupus nephritis (MLN). These data support the hypothesis that individual Th1/Th2 balance is one of the critical determinants for
histopathology of LN.
1.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease, which is characterized by tissue deposition of
circulating immune complexes leading to release of inﬂam-
matorymediators,inﬂuxofinﬂammatorycells,andclinically
apparent disease [1]. It is a prototypic systemic disease and
has the potential to involve the multiple organ system in
contrast to autoimmune diseases such as multiple sclerosis
a n dt y p e1d i a b e t e sm e l l i t u s[ 2]. The renal involvement,
called lupus nephritis (LN), is one of the most serious
complications, and shows the phenotypic and histolog-
ical heterogeneity. In particular, two polar morphologic
forms, diﬀuse proliferative lupus nephritis (DPLN, World
Health Organization (WHO) class IV) and membranous
lupus nephritis (MLN, WHO class V) are representative
of histological ﬁndings in LN [3–5]. DPLN is the most
common, severe, and important form of LN. Hematuria
and proteinuria are present in all DPLN patients with active
disease, and the nephrotic syndrome, hypertension, and
renal insuﬃciency are all frequently seen. Aﬀected patients
typically have signiﬁcant hypocomplementemia (especially
C3) and elevated anti-DNA levels, especially during active
disease [6]. Patients with DPLN usually have an unfavorable
prognosiswithahighpercentageofeventuallyprogressingto
a renal failure despite aggressive treatment [7]. On the other
hand MLN patients would be predicted to have proteinuria
as the most prominent clinical feature and an indolent
course similar to that seen with idiopathic membranous
glomerulonephritis (MGN). It is intriguing that two polar
morphologic forms exit in the same disease, and what
causes the morphologic form determination. Human IgG
molecules are classiﬁed into four IgG subclasses according
to the immunologically distinct constant region of the
heavy chain [8]. The IgG is the most important Ig isotype
in immunopathogenesis for LN, and accordingly, diﬀerent
IgG subclasses have distinct physicochemical and biological
properties. Although it should be recalled that glomerular
deposited IgG subclasses have a role for determination of
morphological form, it was demonstrated that distribution
of subclass in glomerular IgG deposition was not associated
withthediﬀerenthistologicalexpressionsofDPLNandMLN
[9]( Figure 1).
It is widely recognized that na¨ ıve CD4+ Tc e l l sb e c o m e
activated and diﬀerentiate into various eﬀector T cell subsets
after encountering a speciﬁc antigen, T helper type 1 (Th1),2 Journal of Biomedicine and Biotechnology
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Figure1:Twopolarmorphologicformsarerepresentativeofhistologicalﬁndingsinlupusnephritis.(a)DPLNshowsdiﬀusehypercellularity
of endothelial cells and mesangial cells throughout the glomerulus. Peripheral capillary are thickened by subendothelial deposition of
immune complex (x400, PAS staining). (b) On the other hand MLN shows generalized diﬀuse thickening of the peripheral capillary walls
without prominent hypercellularity in the glomerulus (x400, PAS staining). (c) Glomerular IgG subclass deposits in a patient with MLN
determined by immunoﬂuorescence microscopy (x100). IgG subclass deposition was examined using FITC-conjugated mouse antihuman
IgG subclass speciﬁc mAbs.
Th2, and Th17 cells, characterized by distinct patterns of
cytokine production. Th1 cells produce mainly interferon-γ
(IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-γ
(TNF-α), and promote cell-mediated immunity. Th2 cells
secreting IL-4, IL-5, and IL-10 and are associated with
humoralimmuneresponsesandinduceantibodyproduction
[10]. Th17 cells produced IL-17 and drives inﬂammatory
responses. Exaggeration of responses by Th1, Th2, and
Th17 cells can induce tissue inﬂammation and another
subset of regulatory T cells (Treg cells) controls these
eﬀector T cells for maintenance of the immune response
and prevention of autoimmunity and tissue inﬂammation.
Various types of Treg cells have been described that mediate
these regulatory functions. It has been demonstrated that
an imbalance between Th1 and Th2 cytokine production
is much concerned with the induction and development
of several autoimmune diseases. The polarized situation
between Th1 and Th2 cells is established to be important in
animal models and human autoimmune diseases [11].
Although a relationship between SLE activity and
cytokine productions was abundantly reported, cytokine
proﬁles concerned with LN, especially each histologic phe-
notype have not been suﬃciently discussed. In this review
we focus on Th subset, which exerts signiﬁcant eﬀect on the
determination of morphological form in LN.
2.Th1 Subset
A large number of studies suggested that SLE is a Th2-driven
disease [12, 13]. However, elevation of both Th1 and Th2
cytokines occurs in both humans and mice suggesting that
SLE is a complex disease driven by diﬀerent lymphocyte
subsets[14]withheterogeneityofclinicalmanifestationsand
organ involvement.
In human LN, a relationship between histological clas-
siﬁcation and Th1/Th2 balance was suggested. Immuno-
histological study for nephritis showed the large number
of inﬁltrating macrophages, Th1 cells, CD40 positive cells,
and osteopontin in DPLN, but not in MLN [15]. CD40-
CD40L interaction and osteopontin function are known to
be involved in early Th1-mediated cellular immunity [16–
18]. IL-12 is a 70kDa heterodimer (IL12p70) produced
by macrophages and dendritic cells (DC). In conjunction
with IL-18, it promotes IFN-γ production, and leads to
polarization of peripheral cells toward a Th1 phenotype. In
LN both serum and urinary IL-12p70 elevation was reportedJournal of Biomedicine and Biotechnology 3
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Figure 2: Representative two-color dot plots (anti-IL-4 PE versus anti-IFN-γ FITC) from analysis of intracellular cytokines by ﬂow
cytometry. Peripheral whole blood samples obtained from individuals were cultured for 4 hours with PMA and ionomycin in the presence
of brefeldin A. The activated cells were ﬁxed and stained with anti IFN-γ FITC, anti-IL-4 PE, and CD4-PerCP. The cells were then subjected
to ﬂow cytometric analysis on a FACScan ﬂow cytometer (Becton Dickinson). Dot plots (a) and (b) are typical examples of FACS histograms
which have demonstrated contrastive polarization to the Th1- and Th2-like cytokine responses, respectively. (a) histogram for one SLE
patient (age/sex; 48/F) with DPLN. (b) histogram for another SLE patient (age/sex; 21/F) with MLN. The percentage of cells in each of the
quadrants are shown in the right upper corners. The values of the Th1/Th2 ratio are shown in the top of each panel.
and which reﬂected IL-12 production in glomeruli [19].
Although there was no signiﬁcant diﬀerence in the serum
values of IL-12p70 between DPLN and MLN, signiﬁcant
diﬀerence was shown in the urinary value of IL-12p70. It
was also demonstrated that the value of peripheral IFN-γ/IL-
4 ratio in DPLN was much greater than that in MLN, and
these results are coincident with our previous report [20, 21]
(Figures 2 and 3). The fact that activity index for DPLN was
correlated with the value of IFN-γ/IL-4 ratio indicates IFN-γ
plays a principal role in the development of DPLN [21]. It
was also shown that large amounts of IL-18 have been found
within serum and glomeruli of humans LN. However, there
was no diﬀerence between them in DPLN and MLN [19].
MRL/MpJ-lpr/lpr (MRL/lpr)m i c eh a v ep r o v e np a r t i c -
ularly valuable for the investigation of SLE pathogenesis
[22]. MRL/lpr mice develop a lupus-like autoimmune
disease characterized by severe panisotypic hypergamma-
globulinemia, autoantibody production, lymphadenopathy,
and immune complex- (IC-)associated nephritis. Because
MLR/lpr nephritis involves the glomerulus, interstitium, and
vascular components, and shows inﬁltration of macrophages
and T cells, it is considered a suitable histological model
for human DPLN. Moreover, like human DPLN, MLR/lpr
nephritis is associated with Th1 responses [23]. MRL/lpr
mice deﬁcient in the IFN-γ or its receptor developed signif-
icantly reduced DPLN [24, 25]. IL-12 deﬁciency in MRL/lpr
micedelayedDPLNanddiminishedsystemicpathology[26].
It was also demonstrated that IL-18 accelerated DPLN, and
that DPLN was exacerbated by the synergistic action of IL-
12 and IL-18, a combination known to promote Th1 cell
development [27]. Th2 cytokine IL-10 deﬁcient MRL/lpr
mice developed severe DPLN [28]. These results indicate
Th1-dependent mechanism plays a role in the pathogenesis
of DPLN.
3.Th2 Subset
In human LN, MLN is a representative of secondary MGN.
It was suggested a predominant Th2 cytokine response is
associated with MGN pathogenesis [21, 29, 30]. The deposits
stain uniformly with a predominance of IgG4 in idiopathic
MGN [31, 32], and it was suggested that MGN occurs in
individuals who generate IgG4 to M-type phospholipase A2
receptor (PLA2R) [33]. IgG4 is a Th2-dependent IgG sub-
class, and IL-4 directs na¨ ıve human B cells to switch to IgG4
and IgE production [34]. In addition the fact that chronic
graft versus host diseases (cGVHD), in which Th2 immune
response occurs predominantly, occasionally associates with
MGN not diﬀuse proliferative glomerulonephritis (DPGN),
supportsthenotionthatpredominantTh2cytokineresponse
is associated with MGN pathogenesis [35, 36]. While MLN
shows apparently diﬀerent IgG subclass distribution of
deposit [9], and IgG eluted from the glomerular deposits
in the patient with MLN does not recognize PLA2R [33].
However, it was also suggested a predominant Th2 cytokine4 Journal of Biomedicine and Biotechnology
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Figure 3: Distribution of the individual values of Th1/Th2 ratios in
three groups control, DPLN, and MLN patients. Individual values
of the ratio are plotted with the mean (bar) for each group, and
(n) refers to the number of individuals in each group. The mean
± SD values were as follows. Healthy normal control 8.82 ± 4.45,
DPLN 25.89 ± 18.98, and MLN 4.66 ± 4.64, respectively. The value
of DPLN was signiﬁcantly higher than those of normal and MLN. P
values determined by Student’s t-test.
response is associated with MLN pathogenesis [20, 29, 32].
Association study between MLN and IFN-γ gene using
microsatellite polymorphisms demonstrated that half of
the MLN patients were homozygous of the allele of lower
amount of IFN-γ production. This result suggested that the
immune response of SLE patient bearing lower amount of
IFN-γ production genotype is tend to be predominant to
Th2. It was suggested that genetically determined IFN-γ
production should inﬂuence on the histological ﬁnding of
LN [37].
In murine LN, MRL/lpr mice disrupted the WSX-1 gene
developed disease essentially identical with human MLN,
accompanied by marked impairment of Th1-type immune
responses with Th2-type immune deviation [38]( Figure 4).
WSX-1 is a class I cytokine receptor expressed mainly on
T lymphocytes. The initial mounting of Th1 responses
depends on the function of the WSX-1 gene, which encodes
a subunit of the IL-27R with homology to IL-12R [39]. It
is indicated that the phenotypic shift from DPLN to MLN
in MRL/lpr mouse occurred because the loss of WSX-1
impaired the Th1 response and concomitantly enhanced the
Th2 response. These results suggested that Th2-dependent
mechanism plays a role in the pathogenesis of MLN.
4.IL-17ProducingTCellsandTh17 Subset
IL-17 is mostly produced by CD4+,C D 8 +,C D 4 −/CD8−,a n d
γ/δ T-cells, and Th17 cells. In human LN, it was reported
that IL-17 expressing T-cells migrate to the kidney and
contribute to inﬂammatory processes [40]. Expressions of
costimulatory marker CD80 and CD134 on IL-17 producing
T cells in the peripheral blood in SLE patients was increased
as compared to healthy controls. The presence of CD134+T-
cells in the kidney suggests that these cells after ligation
with CD134L expressed by endothelial cells migrate to the
kidney and might contribute to inﬂammatory processes
through IL-17 secretion. However, no signiﬁcant diﬀerence
in the expressions was seen between in patients with DPLN
and MLN. In murine LN, relevant amounts of IL-17 are
produced, and IL-17 producing T-cells largely inﬁltrate the
nephritic kidneys of NZB/NZWF1 mice [41]. By contrast,
treatment with anti-CD3 monoclonal antibodies delayed the
renal damage with concurrent defect of IL-17 production
in both serum and glomeruli [42]. In MRL/lpr mice IL-
1 7p r o d u c i n gT - c e l l sa r i s e sf r o mC D 3 +/CD4−/CD8− subset.
Therefore, this cell population is considered an active
mediator of renal cytotoxicity.
IL-6 promotes the proliferation of renal mesangial cells
and activates na¨ ıve T cell diﬀerentiation towards Th17
cooperatedwithtransforminggrowthfactor-β (TGF-β)[43].
Also it primes the diﬀerentiation of B cells into antibody-
producing cells. In human LN, inﬁltrating inﬂammatory
cells in the kidney, mainly macrophages and monocytes,
are the main source of IL-6. In addition to the high IL-6
serum levels, signiﬁcant overexpression of IL-6 is found in
DPLN whereas healthy kidneys show little IL-6 expression
[44]. In murine LN, blocking IL-6 with anti-IL-6 antibodies
was able to reduce kidney pathology in MRL/lpr [45]
and NZB/NZW mice [46] whereas mice with IL-6 overex-
pression develop mesangial proliferative glomerulonephritis
[47]. IL-6-deﬁcient MRL/lpr mice showed delayed onset
of proteinuria and hematuria compared to control mice.
The absence of IL-6 resulted in signiﬁcant reduction of
inﬁltrating macrophages in the kidney, a decrease in renal
IgG and C3 deposition, and a reduction of CD4+ and CD8+
lymphocytes [48]. These results indicate that IL-6 is a strong
promoter for DPLN.
5.TregSubset
Treg cells are a heterogeneous population of CD4+/
CD8+/CD25+ cells diﬀerentiatedintwosubsets.TheFoxp3−
population includes both IL-10-producing Treg cells and
Th3 cells that produce TGF-β. This cytokine plays crucial
roles in the diﬀerentiation to CD4+CD25+FoxP3+Treg. By
contrast, Foxp3+ Treg cells play a protective role in
autoimmunity. The expression of Foxp3 prevents T-cells
from diﬀerentiating into Th17 proinﬂammatory eﬀector T-
cells [49]. On the other hand TGF-β, together with IL-6,
promotes the diﬀerentiation of Th17 cells and suppresses
FoxP3, leading to a reduction in Treg cells [43]. In human
LN, the proportion of Treg cells in PBMCs and serum
and urinary TGF-β1l e v e l sw e r ee v a l u a t e d .T G F - β1 is the
main immunemodulating member of TGF-β protein. The
results demonstrated a signiﬁcant decrease in the frequency
of CD4+CD25high and CD4+CD25+FoxP3+ Tc e l l si nL N
patients. This decreased Treg cells might enhance autoim-
mune response. This decrease was accompanied with lower
serum TGF-β1 levels and higher urinary TGF-β1l e v e l s[ 50].
It was described that urinary TGF-β reﬂects the grade ofJournal of Biomedicine and Biotechnology 5
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Figure 4:MRL/lpr micedisruptedtheWSX-1genedevelopeddiseaseessentiallyidenticalwithhumanMLN.(a)Arepresentativeglomerulus
of 36-week-old WSX-1−/− MRL/lpr mouse (x400, PAM staining). Arrows indicate spike formation. (b) Electron micrograph (x4000) of the
glomerular capillary of the mouse shows numerous subepithelial electron-dense deposits in the basement membrane (arrows).
interstitial ﬁbrosis in glomerular disease and also the mesan-
gial matrix increase in proliferative glomerulonephritis [51].
The elevated excretion of TGF-β was also shown in the
patient with focal glomerulosclerosis [52]. These results
make us conceive the idea that Th17 cells and Treg cells
may compete with each other in the process of development
of LN, and nevertheless this Th17/Treg balance TGF-β
production may be activated.
In murine LN, depletion of CD4+/CD25+ cells in
NZB/NZWF1 accelerates the onset of DPLN whereas their
transfer into CD4/CD25 KO mice delays the DPLN devel-
opment [53]. The treatment of antimouse thymocyte
globulin (ATG) in conjunction with TGF-β1f o rM R L / lpr
mice demonstrated inhibition of progression of proteinuria
and improvement in long-time survival accompanied with
reducedrenalhistologicalﬁndings.ItwassuggestedthatATG
followed TGF-β1 treatment induced the diﬀerentiation for
CD4+CD25+FoxP3+Treg [54].
Also IL-10 elevation occurs in diﬀerent clinical condi-
tions associated to SLE. Although this cytokine has been
extensively studied, it remains unclear whether elevation of
IL-10isacauseofLNornot.RecentlyIL-10isnotconsidered
as a lineage speciﬁc cytokine, because it has been shown that
not only Th2 cells but also Th1 cells, Th17, and Treg cells can
produce IL-10. We conceive that the overexpression of IL-
10 in SLE might reﬂect IL-10-producing Treg cells activation
against intrinsic defect of the cytokine homeostasis.
6. Conclusions
It is interesting that there are two distinct phenotypes,
DPLN and MLN, in histological ﬁndings of lupus nephritis
despite of being based on the same disease. Although the
determinants that account for these diﬀerences were still
equivocal, recent studies have supported that Th1, IL-17
producing T cells and Th17 cells play a principal role for
DPLN. While Th2 cells may contribute to development
of MLN. Individual Th1/Th2 balance may be one of the
critical determinants for histopathology of LN. Similarly
Treg cells control eﬀector T cells for maintenance of the
immune response, and Treg/Th17 balance may be another
determinant for development of LN.
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